Protocol Summary
Protocol No.LCCC1524-ATLPrincipal InvestigatorShea, Thomas
PhasePhase I
TitlePhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)
DescriptionThe purpose of this research study is to determine a safe dose of the ATLCAR.CD30 cells to give after receiving a transplant. This is the first step in determining whether giving ATLCAR.CD30 cells to others with lymphoma in the future will help them. The researchers also want to find out what side effects patients will have after they receive ATLCAR.CD30 cells post-transplant. This study will also look at other effects of ATLCAR.CD30 cells, including their effect on your cancer and how long they will survive in your body.
Applicable Disease SitesHodgkin Lymphoma
Non-Hodgkin Lymphoma
Drugs InvolvedATLCAR.CD30
StatusOpen
Participating InstitutionsUNC-CH
Wake Forest University
ClinicialTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02663297